2007
DOI: 10.1016/j.tox.2006.11.065
|View full text |Cite
|
Sign up to set email alerts
|

The dilemma of approving antidotes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0
1

Year Published

2009
2009
2021
2021

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 17 publications
0
3
0
1
Order By: Relevance
“…Soma-se a isso a falta de interesse econômico em investir em tecnologias para eventos raros, o que permite classificar os antídotos como produtos "órfãos" e usufruir de vantagens comerciais 50 . Cabe aos governos negociar e garantir o suprimento desses medicamentos essenciais.…”
Section: Discussionunclassified
“…Soma-se a isso a falta de interesse econômico em investir em tecnologias para eventos raros, o que permite classificar os antídotos como produtos "órfãos" e usufruir de vantagens comerciais 50 . Cabe aos governos negociar e garantir o suprimento desses medicamentos essenciais.…”
Section: Discussionunclassified
“…Toxicology data found in prescribing information may be incomplete, outdated, or inaccurate . Lack of overdose data in newly approved medications or outdated treatment recommendations can have significant implications for poisoned patients, as they may receive suboptimal treatment …”
Section: Introductionmentioning
confidence: 99%
“…As the most commonly used dye, MB can reside in lymph nodes for a long time for a cheaper price (Yuan et al, 2000). MB is a reductant-oxidant, which is often used as an antidote in clinical cyanide poisoning (Sun et al, 1995;Steffen, 2007). Recent studies show that it possesses some analgesic effects (Kumar et al, 1995;Tang et al, 1996).…”
Section: Introductionmentioning
confidence: 99%